MaxCyte, Inc. (MXCT) Gross Margin
- Gross margin · 12 months: Value 130.67%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 130.67% | Gross profit / revenue. Period ending 2026-06-30. $24.60M ÷ $18.83M × 100 ≈ 130.67% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 24.60M USD | Gross Profit |
| Revenue | 18.83M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 6.45M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $24.60M | $18.83M | $6.45M | 130.67% |
| 2026-03-31 | $25.99M | $19.71M | $6.29M | 131.84% |
| 2025-12-31 | $26.80M | $20.96M | $6.22M | 127.90% |
| 2025-09-30 | $27.53M | $22.23M | $6.89M | 123.85% |
| 2025-06-30 | $28.53M | $23.23M | $7.22M | 122.79% |
| 2025-03-31 | $30.48M | $22.37M | $7.19M | 136.23% |
| 2024-12-31 | $31.53M | $22.21M | $7.10M | 141.92% |
| 2024-09-30 | $39.21M | $20.92M | $6.39M | 187.45% |
| 2024-06-30 | $40.18M | $19.46M | $5.26M | 206.49% |
| 2024-03-31 | $38.91M | $20.12M | $5.14M | 193.41% |
| 2023-12-31 | $36.55M | $19.50M | $4.74M | 187.44% |
| 2023-09-30 | $33.33M | $22.50M | $4.72M | 148.15% |
| 2023-06-30 | $35.39M | $25.50M | $5.29M | 138.83% |
| 2023-03-31 | $36.21M | $26.86M | $5.04M | 134.85% |
| 2022-12-31 | $39.16M | $28.75M | $5.10M | 136.22% |
| 2022-09-30 | $37.21M | $28.50M | $4.78M | 130.58% |
| 2022-06-30 | $37.13M | $26.95M | $4.35M | 137.77% |
| 2022-03-31 | $34.97M | $24.19M | $4.02M | 144.56% |
| 2021-12-31 | $30.25M | $21.57M | $3.65M | 140.22% |
| 2021-09-30 | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) |
| 2020-12-31 | $23.40M | $15.45M | $2.77M | 151.45% |
| 2020-09-30 | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) |
| 2019-12-31 | $19.12M | $13.26M | $2.50M | 144.23% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |